Shakespeare’s Hamlet uttered “to be or not to be, that is the question”. Well, large employer groups face a new question, “to sue or not to sue”. Perhaps a little dramatic, but in the rapidly evolving landscape of healthcare and drug... Read More
The pharmacy benefits landscape is changing for large employer groups and affecting all parties in the drug supply chain. Recent federal actions, such as the Federal Trade Commission’s investigation into Pharmacy Benefit Managers (“PBMs”)... Read More
“The broker not only gives bad advice to the employer that’s in the broker’s self-interest, but the broker also allows the big PBM to write crazy terms into a contract. It’s unethical. It’s beyond unethical.” - Jonathan Levitt Did... Read More
Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Commerce on May 12, 2023. In this... Read More
In a significant development that could impact the future of prescription drug costs, the U.S. Federal Trade Commission (“FTC”) announced an expansion of its investigation into the country’s leading Pharmacy Benefit Managers (“PBMs”). ... Read More
Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Executive on May 12, 2023. In this... Read More
As discussed in our recent article, the Consolidated Appropriations Act of 2021 (the “CAA”) levels the playing field between pharmacy benefit managers (“PBMs”) and their employee healthcare benefit plan clients (“Plans”) by creating new... Read More
A new federal law has brought significant change in the design of pharmacy benefit plans, leveling the playing field between pharmacy benefit managers (“PBMs”) and their employee healthcare benefit plan (“Plan”) clients. For far too long,... Read More
The healthcare and life science industries should be aware of the recent increase in False Claims Act (“FCA”) or “whistleblower” cases. In fiscal year 2022, the Department of Justice (“DOJ”) recovered $2.2 billion under the FCA. In 2021,... Read More
On January 25, 2023, the Court in Johnson & Johnson v. SaveOnSP dismissed SaveOnSP’s motion to dismiss, allowing Johnson & Johnson’s (“JNJ”) claims to proceed. As we reported here, JNJ filed a lawsuit against SaveOnSP alleging that... Read More
